EP0712931A3
Interferon-gamma production inducing polypeptide, monoclonal antibody, and agent for interferon-gamma susceptive disease
Abstract
A polypeptide which has a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The polypeptide strongly induces the IFN-γ production by immunocompetent cells with only a small amount, and dose not cause serious side effects even when administered to human in a relatively-high dose. It is readily prepared by using a monoclonal antibody obtained from hybridomas, and incorporated into agents for treating and/or preventing malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases.
Term
Term ended
Projected expiry passed 10 November 2015, 10.9 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 1 of 2
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| WO9205256A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report | 1-47 |
| DATABASE WPI Section Ch Week 9347, Derwent World Patents Index; Class B04, AN 93-374598, XP002024314 | Non-patent | – | – | Search report | – |
| H. OKAMURA ET AL.: "Cloning of a new cytokine that induces IFN-gamma production by T cells", NATURE, vol. 378, no. 6552, 2 November 1995 (1995-11-02), LONDON GB, pages 88 - 91, XP002024313 | Non-patent | – | – | Search report | – |
71 members in 11 offices
Priority claims15
| Document | Office | Kind | Date |
|---|---|---|---|
| 30420394 | Japan | – | |
| 30420394 | Japan | A | |
| 5824095 | Japan | – | |
| 5824095 | Japan | A | |
| 7835795 | Japan | – | |
| 7835795 | Japan | A | |
| 26206295 | Japan | – | |
| 26206295 | Japan | A | |
| 27498895 | Japan | – | |
| 27498895 | Japan | A | |
| JP19940304203 | – | – | – |
| JP19950058240 | – | – | – |
| JP19950078357 | – | – | – |
| JP19950262062 | – | – | – |
| JP19950274988 | – | – | – |
Members71
| Document | Office | Kind | |
|---|---|---|---|
| EP0709463A1 | European Patent Office (EPO) | A1 | |
| CA2162353A1 | Canada | A1 | |
| EP0712931A2 | European Patent Office (EPO) | A2 | |
| KR960014353A | Republic of Korea | A | |
| AU3779695A | Australia | A | |
| KR960017686A | Republic of Korea | A | |
| JPH08154696A | Japan | A | |
| JPH08193098A | Japan | A | |
| JPH08231598A | Japan | A | |
| EP0712931A3This record | European Patent Office (EPO) | A3 | |
| CA2186423A1 | Canada | A1 | |
| EP0767178A1 | European Patent Office (EPO) | A1 | |
| KR970015601A | Republic of Korea | A | |
| AU6588196A | Australia | A | |
| JPH09157180A | Japan | A | |
| JPH09289896A | Japan | A | |
| JPH107699A | Japan | A | |
| JP2724987B2 | Japan | B2 | |
| US5811271A | United States of America | A | |
| NZ299943A | New Zealand | A | |
| AU700948B2 | Australia | B2 | |
| JP2952750B2 | Japan | B2 | |
| EP0962531A2 | European Patent Office (EPO) | A2 | |
| EP0962531A3 | European Patent Office (EPO) | A3 | |
| TW399099B | Taiwan Province of China | B | |
| AU724940B2 | Australia | B2 | |
| EP0712931B1 | European Patent Office (EPO) | B1 | |
| US6197297B1 | United States of America | B1 | |
| EP0709463B1 | European Patent Office (EPO) | B1 | |
| DK0712931T3 | Denmark | T3 | |
| DE69520088D1 | Germany | D1 | |
| US6207641B1 | United States of America | B1 | |
| US6214584B1 | United States of America | B1 | |
| DE69520322D1 | Germany | D1 | |
| TW430670B | Taiwan Province of China | B | |
| US6242255B1 | United States of America | B1 | |
| ES2156199T3 | Spain | T3 | |
| US6268486B1 | United States of America | B1 | |
| DE69520322T2 | Germany | T2 | |
| US2001018212A1 | United States of America | A1 | |
| TW464656B | Taiwan Province of China | B | |
| US6403079B1 | United States of America | B1 | |
| US6441138B2 | United States of America | B2 | |
| US6509449B1 | United States of America | B1 | |
| KR100374450B1 | Republic of Korea | B1 | |
| US2003129184A1 | United States of America | A1 | |
| JP2003327542A | Japan | A | |
| TW581771B | Taiwan Province of China | B | |
| DE69520088T2 | Germany | T2 | |
| JP3629264B2 | Japan | B2 | |
| KR100491365B1 | Republic of Korea | B1 | |
| KR100491366B1 | Republic of Korea | B1 | |
| KR100490447B1 | Republic of Korea | B1 | |
| EP0712931B2 | European Patent Office (EPO) | B2 | |
| DK0712931T4 | Denmark | T4 | |
| US7135458B1 | United States of America | B1 | |
| DE69520088T3 | Germany | T3 | |
| ES2156199T5 | Spain | T5 | |
| US2007031403A1 | United States of America | A1 | |
| JP3897316B2 | Japan | B2 | |
| CA2186423C | Canada | C | |
| JP2007197452A | Japan | A | |
| JP3993652B2 | Japan | B2 | |
| JP4004088B2 | Japan | B2 | |
| US7355014B2 | United States of America | B2 | |
| US7405048B2 | United States of America | B2 | |
| EP0962531B1 | European Patent Office (EPO) | B1 | |
| DE69535989D1 | Germany | D1 | |
| DK0962531T3 | Denmark | T3 | |
| ES2329099T3 | Spain | T3 | |
| CA2162353C | Canada | C |
59 legal events, as 8 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Patent ceasedCeasedPL | PL | CH | |
| Ep patent expiredExpiredEUP | EUP | DK | |
| Patent expired because of reaching the maximum lifetime of a patentExpiredMK | MK | NL | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Name/firm changedPFA | PFA | CH | |
| Patent modifiedDC2A | DC2A | ES | |
| Fr: translation filed ** decision concerning oppositionOppositionET3 | ET3 | EP | |
| Nl: receipt of modified translations in the netherlands language after an opposition procedureOppositionNLR3 | NLR3 | EP | |
| Amended ep patent with danish claimsT4 | T4 | DK | |
| Ep patent has been republished in amended form after opposition at epoOppositionRPEO | RPEO | SE | |
| Nl: decision of oppositionOppositionNLR2 | NLR2 | EP | |
| Scope or validity of the patent modifiedMAINTIEN DU BREVET DONT L'ETENDUE A ETE MODIFIEEAEN | AEN | CH | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| Reply of patent proprietor to notice(s) of oppositionOppositionORIGINAL CODE: EPIDOS OBSOPLBF | PLBF | EP | |
| Reply of patent proprietor to notice(s) of oppositionOppositionORIGINAL CODE: EPIDOS OBSOPLBF | PLBF | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| Reply of patent proprietor to notice(s) of oppositionOppositionORIGINAL CODE: EPIDOS OBSOPLBF | PLBF | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Unpublished change to opponent dataORIGINAL CODE: EPIDOS OPPOPLBQ | PLBQ | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Corresponds to:REF | REF | EP | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Fr: translation filedET | ET | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| New agentNV | NV | CH | |
| Designated contracting statesAK | AK | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0712931
- Publication, DOCDB
- 0712931
- Publication, EPODOC
- EP0712931
- Application
- 95308055
- Application, DOCDB
- 95308055
- Application, EPODOC
- EP19950308055
Titles3
- German
- Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten
- English
- Interferon-gamma production inducing polypeptide, monoclonal antibody, and agent for interferon-gamma susceptive disease
- French
- Polypeptide induisant la production d'interféron-gamma anticorps monoclonal, et composition pour le traitement ou la prévention de maladies sensibles à l'interféron gamma
Classification
- CPC, 6
- C07K16/244
- A61K38/00
- C07K14/52
- C07K14/54
- C07K16/24
- Y02A50/30
- IPC, 10
- A61K38 00
- A61K38 19
- C07K14 52
- C07K14 54
- C07K16 24
- C12N1 21
- C12N5 20
- C12N15 19
- C12N15 24
- G01N33 68
Designated states1
- Contracting states, 1
- Sweden